Tags : Breakthrough Therapy Designation

Beigene’s Zanubrutinib (BGB-3111) Receives the US FDA’s Breakthrough Therapy Designation

Shots: The BT designation follows the P-II trial assessing Zanubrutinib in patients with 1L mantle cell lymphoma Beigene’s Zanubrutinib is being evaluated globally in seven P-III trials in multiple areas including one for patients with waldenstrom macroglobulinemia (WM) with zanubrutinib vs ibrutinib and P-II for r/r follicular lymphoma in combination with Gazyva (obinutuzumab) Zanubrutinib (BGB-3111) […]Read More